

Clinical Policy: Lamotrigine (Lamictal XR, Lamictal ODT, Subvenite)

Reference Number: CP.CPA.97

Effective Date: 11.16.16

Last Review Date: 08.25

Line of Business: Commercial

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Lamotrigine (Lamictal XR[®], Lamictal ODT[®], Subvenite[®]) is an anticonvulsant.

FDA Approved Indication(s)

Lamictal XR is indicated for:

- Adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.
- Conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED).

Limitation(s) of use: Safety and effectiveness in patients younger than 13 years have not been established.

Lamictal ODT and Subvenite are indicated for:

- Epilepsy – adjunctive therapy in patients aged 2 years and older:
 - partial-onset seizures.
 - primary generalized tonic-clonic seizures.
 - generalized seizures of Lennox-Gastaut syndrome.
- Epilepsy – monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED.
- Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy.

Limitation(s) of use: Treatment of acute manic or mixed episodes is not recommended.

Effectiveness of Lamictal or Subvenite in the acute treatment of mood episodes has not been established.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Lamictal XR, Lamictal ODT, and Subvenite are **medically necessary** when the following criteria are met.

I. Initial Approval Criteria

A. Epilepsy, Bipolar Disorder (must meet all):

1. For Lamictal XR ONLY: Member must use generic immediate-release lamotrigine, unless contraindicated or clinically significant adverse effects are experienced;
2. For Lamictal ODT and Subvenite ONLY: Member meets both of the following (a and b):
 - a. Documentation supports inability to swallow tablets or capsules or member has a documented swallowing disorder;
 - b. For brand name Lamictal ODT requests, member must use generic lamotrigine orally disintegrating tablets, unless contraindicated or clinically significant adverse effects are experienced;
3. Dose does not exceed any of the following (a, b, or c):
 - a. Lamictal XR: 600 mg per day;
 - b. Lamictal ODT: 500 mg per day;
 - c. Subvenite: 500 mg per day.

Approval duration: 12 months or duration of request, whichever is less

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

II. Continued Therapy

A. Epilepsy, Bipolar Disorder (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Lamictal ODT, Lamictal XR, or Subvenite for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. For Lamictal XR ONLY: Member must use generic immediate-release lamotrigine, unless contraindicated or clinically significant adverse effects are experienced;
4. For Lamictal ODT ONLY: Member must use generic lamotrigine orally disintegrating tablets, unless contraindicated or clinically significant adverse effects are experienced;
5. If request is for a dose increase, new dose does not exceed any of the following (a, b, or c):
 - a. Lamictal XR: 600 mg per day;

- b. Lamictal ODT: 500 mg per day;
- c. Subvenite: 500 mg per day.

Approval duration: 12 months or duration of request, whichever is less

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

AED: antiepileptic drug

ODT: orally disintegrating tablet

FDA: Food and Drug Administration

XR: extended release

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|--|---|---|
| lamotrigine (Lamictal [®] , Lamictal ODT), immediate-release tablets, orally disintegrating tablets | Dosing is based on concomitant medications, indication, and patient age. Refer to full prescribing information. | In seizure disorders, individualize to the patient's age, weight, indication, concurrent medication, and clinical response. In bipolar disorder, maximum monotherapy dosage is 200 mg/day PO; 100 mg/day PO if taking valproate; 400 mg/day PO if taking enzyme-inducing drugs while NOT taking valproate. |

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients
- Boxed warning(s): serious skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis, rash-related death; benign rashes)

V. Dosage and Administration

| Drug Name | Indication | Dosing Regimen | Maximum Dose |
|---|-------------------|---|---|
| Lamotrigine ODT (Lamictal ODT), lamotrigine oral suspension (Subvenite) | Epilepsy | <p>Patients > 12 years of age: 25 mg PO QOD to 500 mg PO QD, in 2 divided doses</p> <p>Patients aged 2 to 12 years: 0.15-15 mg/kg/day PO, in 2 divided doses</p> <p>Refer to full prescribing information for specific dosing recommendations depending upon concomitant AEDs or other concomitant medications, indication, and patient age.</p> | <p>Patients > 12 years of age: 500 mg/day</p> <p>Patients aged 2 to 12 years: 400 mg/day</p> |
| | Bipolar | <p>25 mg PO QOD to 400 mg PO QD, in divided doses</p> <p>Refer to full prescribing information for specific dosing recommendations depending upon concomitant AEDs or other concomitant medications, indication, and patient age.</p> | 400 mg/day |
| Lamotrigine XR (Lamictal XR) | Epilepsy | <p>25 mg PO QOD to 600 mg PO QD</p> <p>Refer to full prescribing information for specific dosing recommendations depending upon concomitant AEDs or other concomitant medications, indication, and patient age.</p> | 600 mg/day |

VI. Product Availability

| Drug Name | Product Availability |
|---|--|
| Lamotrigine XR (Lamictal XR) | Extended-release tablets: 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 300 mg |
| Lamotrigine ODT (Lamictal ODT) | ODT tablets: 25 mg, 50 mg, 100 mg, 200 mg |
| Lamotrigine oral suspension (Subvenite) | Oral suspension: 10 mg/mL |

VII. References

1. Lamictal XR Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; April 2025. Available at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Lamictal_XR/pdf/LAMICTAL-XR-PI-MG.PDF. Accessed June 6, 2025.
2. Lamictal ODT Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; April 2025. Available at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Lamictal/pdf/LAMICTAL-PI-MG.PDF. Accessed June 6, 2025.
3. Subvenite Oral Suspension Prescribing Information. Lisle, IL: OWP Pharmaceuticals, Inc.; September 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218879s000lbl.pdf. Accessed October 20, 2025.
4. Micromedex Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Healthcare. Updated periodically. Accessed June 5, 2024.
5. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2018. Available at: <http://www.clinicalpharmacology-ip.com/>.
6. Gloss D, Pargeon K, Pacl A, et al. Practice advisory update: Antiseizure medication withdrawal in seizure-free patients - report of the Guideline Subcommittee of the American Academy of Neurology. *Neurology* 2021;97:1072-81. doi:10.1212/WNL.0000000000012944.
7. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord*. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609.
8. Yatham LN, Chakrabarty T, Bond DJ, et al. CANMAT and ISBD recommendations for the management of patients with bipolar disorder with mixed presentations. *Bipolar Disord*. 2021 Dec;23(8):767-788. doi: 10.1111/bdi.13135.
9. VA/DoD Management of Bipolar Disorder Work Group. VA/DoD clinical practice guideline version 2.0. Washington, D.C.: U.S. Government Printing Office. 2023;1-220.

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|---|----------|-------------------|
| 3Q 2021 annual review: no significant changes; revised Lamictal XR redirection to “Member must use” language; added standard language for continuation of care for reauthorization requests; references reviewed and updated. | 04.20.21 | 08.21 |
| Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less | 01.20.22 | 05.22 |
| 3Q 2022 annual review: no significant changes; references reviewed and updated. | 05.11.22 | 08.22 |
| Template changes applied to other diagnoses/indications. | 09.28.22 | |
| 3Q 2023 annual review: no significant changes; references reviewed and updated. | 04.19.23 | 08.23 |

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|--|----------|-------------------|
| 3Q 2024 annual review: no significant changes; references reviewed and updated with CANMAT treatment guidelines on bipolar disorder per Compliance request. | 07.23.24 | 08.24 |
| 3Q 2025 annual review: no significant changes; added generic redirection for Lamictal ODT and clarified that the redirection for Lamictal XR should be to the generic IR tablets; references reviewed and updated. | 06.06.25 | 08.25 |
| RT4: added newly approved dosage form, Subvenite oral suspension. | 10.10.25 | |

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.